- Conditions
- Healthy Volunteer
- Interventions
- plerixafor, Placebo
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 20 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- plerixafor
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- La Jolla, California • Columbus, Ohio • Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Plerixafor
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 8
- States / cities
- Duarte, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Interventions
- Plerixafor
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Sickle Cell Disease
- Interventions
- Plerixafor
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Sickle Cell Disease Without Crisis
- Interventions
- Plerixafor
- Drug
- Lead sponsor
- Alessandra Biffi
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- AMD3100, Mitoxantrone, Etoposide, Cytarabine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Relapsed/Refractory AML, Relapsed/Refractory ALL, Secondary AML/MDS, Acute Leukemia of Ambiguous Lineage, AML, ALL
- Interventions
- Plerixafor Dose Escalation
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 3 Years to 29 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Denver, Colorado • Atlanta, Georgia + 5 more
- Conditions
- Healthy Volunteers
- Interventions
- MGTA-145, plerixafor, Placebo
- Biological
- Lead sponsor
- Ensoma
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Plerixafor, bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Hyannis, Massachusetts • Milford, Massachusetts + 2 more
- Conditions
- Osteosarcoma, Bone Metastases
- Interventions
- 153Sm-DOTMP, External beam radiotherapy., Calcium Carbonate, Mozobil, Neupogen Injectable Product
- Drug · Radiation
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 15 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- The Bronx, New York